ChatGPT

Perplexity

Gemini

Claude

Grok

Health Answers by Pfizer: Your Health. Your Answers.

Winner of the 2025 People's Voice Webby Award in the Health & Wellness AI, Immersive & Games category.

Health Answers by Pfizer is a free health 

We believe that good food equals a good mood, but we get it. It’s hard to find time in your busy day to take a break and enjoy a nice meal that’s made just for you. 
With Pfizer Café, Compass Group wi

The Pfizer Innovation Research App (PfIRe App), is an iPhone app that utilizes AppleWatch and HealthKit to collect health information including physical activity, sleep, and heart rate/variability. It

A smartphone application for capturing and documenting skin depigmentation photos

LivingWith® is designed to help you connect with loved ones, ask for the support you need, remember important information from doctors’ visits, stay organized and focus on your wellbeing - all in one 

Pfizer

Ever Wonder How Medicines Get Their Names?

Challenging convention and thinking big, especially in the face of uncertainty or adversity, by speaking up and being decisive to drive breakthrough innovation

Courage

Performing at our best together by focusing on what matters, agreeing who does what, and measuring outcomes to change patients' lives

Excellence

Ensuring every person deserves to be seen, heard, and cared for through inclusive practices, acting with integrity, and reducing healthcare disparities

Equity

Finding fulfillment by taking pride in our work, recognizing one another's contributions, and having fun while pursuing our mission

Pfizer is a leading global biopharmaceutical company founded in 1849, generating $63.6 billion in 2024 revenue through innovative medicines and vaccines across oncology, infectious diseases, and cardiometabolic conditions. With 88,000+ employees and $10.8B in annual R&D investment, Pfizer delivers breakthrough therapies guided by its mission of changing patients' lives.

Pfizer's oral Covid-19 antiviral cuts hospitalization, death by 85%

Pfizer is testing a pill that, if successful, could cure Covid-19

Pfizer vaccine appears effective against mutation in new coronavirus variants

Pfizer Covid vaccine approved for use next week in UK

Reverse Engineering the Source Code of the BioNTech/Pfizer SARS-CoV-2 Vaccine

Dr. Albert Bourla

Chairman & Chief Executive Officer

David M. Denton

Chief Financial Officer & Executive Vice President

Dr. Chris Boshoff

Chief Scientific Officer & President, Research & Development

Aamir Malik

Chief U.S. Commercial Officer & Executive Vice President

Dr. Andrew Baum

Chief Strategy & Innovation Officer & Executive Vice President

An oral anticoagulant prescribed to millions of patients to prevent stroke and blood clots in patients with atrial fibrillation and treat deep vein thrombosis and pulmonary embolism. Eliquis is Pfizer's top-selling product and has strengthened its leadership position in the growing oral anticoagulant market.

Eliquis (apixaban)

A family of pneumococcal conjugate vaccines including Prevnar 20/Apexxnar and Prevnar 13/Prevenar 13 for both pediatric and adult populations, protecting against invasive pneumococcal disease and pneumonia caused by Streptococcus pneumoniae bacteria.

Prevnar Family

An oral antiviral treatment for COVID-19 in adults at high risk of progressing to severe disease. Paxlovid combines nirmatrelvir and ritonavir and was a critical tool in the pandemic response, generating significant revenue through government contracts.

Paxlovid

A breakthrough treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and progressive disease affecting the heart. These therapies have transformed outcomes for patients with this previously difficult-to-treat condition.

Vyndaqel/Vyndamax (tafamidis)

Pfizer-BioNTech COVID-19 vaccine using mRNA technology, the first COVID-19 vaccine to receive FDA approval. Comirnaty was developed in record time and became critical in the global pandemic response, demonstrating the power of mRNA vaccine platforms.

Comirnaty

A targeted cancer therapy and CDK4/6 inhibitor used in combination with endocrine therapy for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in women and men.

Ibrance (palbociclib)

An antibody-drug conjugate (ADC) acquired through the Seagen acquisition, approved for treatment of urothelial cancer. Padcev exemplifies Pfizer's leadership in ADC technology and generated $1.59 billion in 2024 revenue under Pfizer.

Padcev (enfortumab vedotin)

Pfizer completed its acquisition of Metsera for $65.60 per share in cash, representing approximately $7.0 billion in enterprise value, plus contingent value rights up to $20.65 per share. The acquisition added a portfolio of GLP-1 and weight management candidates including MET-097i entering Phase 3 development, MET-233i monthly amylin analog, and an oral GLP-1 RA in Phase 1.

Pfizer Completes Acquisition of Metsera for $7 Billion

Pfizer announced an exclusive licensing agreement with 3SBio for SSGJ-707, a bispecific antibody targeting PD-1 and VEGF for cancer treatment. The deal includes an upfront payment of $1.25 billion and strengthens Pfizer's oncology pipeline with innovative immunotherapy candidates.

Pfizer Enters $1.25 Billion Licensing Agreement with 3SBio

Pfizer reported full-year 2024 revenues of $63.6 billion, up 7% operationally, with non-COVID products growing 12% operationally. The company provided 2025 revenue guidance of $61-64 billion and adjusted EPS guidance of $2.80-$3.00, while completing cost realignment program expected to deliver $4.5B in savings.

Pfizer Reports Strong Full-Year 2024 Results, Provides 2025 Guidance

Pfizer announced plans to advance up to nine new pivotal Phase 3 trials in oncology in 2025 at the ASCO Annual Meeting, demonstrating commitment to its goal of doubling the number of patients treated with oncology medicines by 2030. The company showcased progress across its deep pipeline of next-generation cancer medicines.

Pfizer Advances Bold Vision for Cancer Care at ASCO 2025

Pfizer reported Q3 2024 revenues of $17.7 billion, up 32% operationally year-over-year, with non-COVID products growing 14% operationally. Adjusted EPS of $1.06 was up 58% versus prior year. The company raised full-year 2024 revenue guidance to $61-64 billion and EPS guidance to $2.75-$2.95, driven by strong Paxlovid sales and oncology growth.

Pfizer Delivers Strong Q3 2024 Results, Raises Guidance

Pfizer announced receiving 14 approvals from the U.S. FDA in 2024, including a second hemophilia medicine to prevent or reduce bleeding episodes, RSV vaccine approval for adults 18-59 at increased risk, and accelerated approval for BRAFTOVI in BRAF V600E-mutant metastatic colorectal cancer, demonstrating robust innovation.

Pfizer Receives 14 FDA Approvals in 2024, Strengthening Pipeline

The White House is moving forward with a "TrumpRX" website to sell medicine at lower prices, following an agreement with Pfizer. What are your thoughts?

Pfizer employees were given a *special batch*… different from what was forced into the general population

I’m the former head of Pfizer R&amp;D. I’m very worried about biopharma’s future

[PFE] Pfizer at ~$26 is a textbook value play hiding in plain sight. Here's why the market is wrong.

Never-ending layoffs in Pfizer?

Pfizer impending layoffs for next couple of months

Anyone here work at Pfizer?

Pfizer Yields ~6%. Do you consider this a bargain?

biotech

AskReddit

conspiracy

ValueInvesting

dividends

PFIZER INC

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases

COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine

Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine.

Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada

Charles Pfizer and Charles F. Erhart, two cousins from Germany, founded Charles Pfizer & Company in a red-brick building in Williamsburg, Brooklyn, with $2,500 borrowed from Charles Pfizer's father. They combined chemistry and confectionery skills to create palatable medicinal products.

Pfizer Founded in Brooklyn

During the American Civil War, Pfizer supplied vital medical treatments including tartaric acid and cream of tartar to the Union Army, propelling a period of unprecedented growth and establishing the company as a reliable pharmaceutical supplier.

Civil War Drives Growth

The company was formally incorporated in New Jersey as Charles Pfizer & Company Inc., establishing a modern corporate structure that would support future expansion and growth.

Corporate Incorporation

Pfizer penicillin arrived with Allied forces on the beaches of Normandy on D-Day, marking the company's successful response to the U.S. government's call to mass-produce penicillin during World War II and ushering in the age of modern medicine.

Mass Production of Penicillin

Pfizer acquired Warner-Lambert in a blockbuster $90 billion deal, gaining full ownership of Lipitor (atorvastatin), which became the world's best-selling drug with over $12 billion in annual sales at its peak.

Warner-Lambert Acquisition

Pfizer acquired Pharmacia for $60 billion, creating a pharmaceutical company with $46 billion in annual sales and significantly expanding Pfizer's product portfolio and global reach.

Pharmacia Acquisition

Pfizer completed the acquisition of Wyeth in a cash-and-stock transaction valued at $68 billion. This purchase diversified Pfizer beyond small molecules into biologics, vaccines, and consumer health, bringing blockbusters like Prevnar and Enbrel to the portfolio.

Wyeth Acquisition

Dr. Albert Bourla was elected CEO of Pfizer in January 2019 and became Chairman in February 2019, accelerating Pfizer's transformation into a more science-driven company by divesting non-science-based businesses and increasing R&D budgets.

Albert Bourla Becomes CEO

Pfizer closed its $43 billion acquisition of Seagen Inc., a global biotechnology leader in antibody-drug conjugates (ADCs), doubling Pfizer's oncology pipeline and establishing leadership in ADC therapeutics. Seagen brought four marketed ADCs including Padcev.

Seagen Acquisition Completed

Pfizer celebrated its 175th anniversary in 2024, marking nearly two centuries of scientific innovation and breakthrough therapies that have changed millions of lives worldwide, from the company's founding in 1849 to becoming a global pharmaceutical leader.

175th Anniversary Celebration

Pfizer reported Q3 2024 revenues of $17.7 billion, representing 32% year-over-year operational growth, with non-COVID products showing 14% operational revenue growth. Adjusted EPS of $1.06 was up 58% compared to prior year, leading to raised full-year guidance.

Strong Q3 2024 Results

Pfizer received 14 approvals from the U.S. FDA in 2024, including a second hemophilia medicine, RSV vaccine expansion for adults 18-59 at increased risk, and accelerated approval for BRAFTOVI in colorectal cancer, demonstrating robust pipeline productivity.

14 FDA Approvals in 2024

Pfizer entered an exclusive licensing agreement with 3SBio for SSGJ-707, a bispecific antibody targeting PD-1 and VEGF for cancer treatment, with an upfront payment of $1.25 billion, strengthening the oncology pipeline.

3SBio Licensing Agreement

Pfizer completed acquisition of Metsera for $65.60 per share in cash, representing an enterprise value of approximately $7.0 billion, plus contingent value rights up to $20.65 per share. The deal added a portfolio of GLP-1 and weight management candidates including weekly and monthly injectables entering Phase 3.

Metsera Acquisition

American multinational pharmaceutical and biotechnology corporation

YouShift is a shift-management app built specifically for doctors and healthcare professionals. Stay organized, save time, and manage your work schedule effortlessly from one secure, easy-to-use platf

AI-powered OS for healthcare staffing, starting with scheduling AI agents for hospitals and clinics

Jota Chamorro

Co-founder

Adolfo Roquero Gimenez

Lucía Vives Martorell

Automated shift scheduling that considers staff preferences, availability, and compliance

AI Scheduling Agents

Comprehensive workforce management platform for healthcare organizations

Pfizer vs YouShift

Pfizer

About

YouShift

About

AI Visibility Head-to-Head

Also Compare

Track AI Visibility in Real Time